logo
Plus   Neg
Share
Email

AstraZeneca: Roxadustat Phase III Pooled Analyses Show Positive Efficacy

AstraZeneca plc (AZN.L,AZN) and FibroGen Inc. have reported pooled efficacy and cardiovascular safety analyses from the Phase III programme assessing roxadustat for the treatment of patients with anaemia from chronic kidney disease. The company said the results demonstrated the potential of roxadustat to address significant unmet medical needs among patients with anaemia from chronic kidney disease, particularly for those who have recently started dialysis.

The primary efficacy endpoint was achieved in the pooled analyses for non dialysis-dependent and dialysis-dependent patients, and in all individual Phase III trials. The study data will form part of the regulatory submission in the US, which is anticipated in the fourth quarter of 2019.

Mene Pangalos, Executive Vice President, BioPharmaceuticals, R&D, said: "The pooled analyses showed incident dialysis patients receiving roxadustat had a lower risk of cardiovascular events which is important as these patients may experience higher rates of morbidity and mortality than those on stable dialysis."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The former chief executive officer of Hertz Global Holdings, Mark Frissora, agreed to pay about $2.2 million to settle the U.S. Securities and Exchange Commission's claims that he played a key role in causing the now-bankrupt car-rental company to file inaccurate financial statements in 2013. Daimler AG, the maker of Mercedes-Benz cars, said Thursday that it has agreed to pay more than $2.2 billion to settle U.S. claims over emissions from its diesel vehicles. A new class-action lawsuit filed against Facebook accuses the company's photo and video-sharing app Instagram of illegally collecting biometric data of as many as 100 million users without their consent, according to reports. The lawsuit filed in a state court in California, alleges that Instagram uses its photo-tagging technology to create a database of users' facial features.
Follow RTT